Geburtshilfe Frauenheilkd 2016; 76 - P294
DOI: 10.1055/s-0036-1592793

Urethral bulking for recurrent stress urinary incontinence after previous midurethral sling

I Zivanovic 1, O Rautenberg 1, K Lobodasch 2, G von Bünau 3, C Walser 1, V Viereck 1
  • 1Kantonsspital Frauenfeld, Frauenfeld, Schweiz
  • 2DRK Krankenhaus Chemnitz-Rabenstein, Chemnitz, Deutschland
  • 3Coombe Women and Infants University Hospital, Dublin, Irland

Aims: To assess the effectiveness of a polyacrylamide hydrogel (PAHG; Bulkamid®) in treating recurrent stress urinary incontinence (SUI) following a previous midurethral sling (MUS) implant.

Methods: This observational study conducted since 2009 included 60 patients with recurrent SUI and mixed urinary incontinence (MUI) after a previous MUS and chose to be treated with the PAHG. Objective and subjective outcomes were assessed at 1, 6 and 12 months after the initial injection. Patients were classified as cured based on a negative cough test (supine and standing) and < 2 g on 1h pad test and a VAS score improved by ≥90%. Improved were those with the loss of only a few drops of urine during the cough test and 2 – 10 g urine on 1h pad test or a reduction > 50% compared with preoperative urine loss and a VAS score improved by ≥75%.

Results: The volume of PAHG injected ranged from 1 to 3 ml. Cured/improved rates were 93.3% (56/60), 88.3% (53/60) and 83.6% (46/55) at 1, 6 and 12 months, respectively. Patients with MUI had a cured urge urinary incontinence in 36.8%, 47.4% and 38.9%, respectively. Voiding dysfunction rates were 13.3%, 8.3% and 1.8% at 1, 6 and 12 months and urinary tract infection rates were 5%, 11.7% and 3.6%, respectively. Other adverse events were short-term and/or observed in < 4% of patients.

Conclusions: PAHG can be used to treat recurrent SUI and MUI after previous MUS with good outcome and low complication rates.